Director at Gyre Therapeutics (GYRE) granted 40,000 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Gyre Therapeutics director Carmichael Gordon received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $5.95 per share, expire on June 10, 2036, and will vest in 12 equal monthly installments through June 10, 2027, contingent on continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Carmichael Gordon
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 40,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 40,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 40,000 options
Exercise price: $5.95 per share
Expiration date: June 10, 2036
+2 more
5 metrics
Options granted
40,000 options
Stock Option (Right to Buy) grant on June 10, 2026
Exercise price
$5.95 per share
Conversion or exercise price of options
Expiration date
June 10, 2036
Option expiration for 40,000-share grant
Post-grant option holdings
40,000 options
Total derivative securities following transaction
Vesting schedule
12 monthly installments
Vesting through June 10, 2027, subject to continued service
Key Terms
Stock Option (Right to Buy), Common Stock, Grant, award, or other acquisition, vesting
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
vesting financial
"which will vest in 12 equal monthly installments through June 10, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transaction did GYRE director Carmichael Gordon report?
Carmichael Gordon reported receiving a grant of stock options for 40,000 shares of Gyre Therapeutics common stock. These options are compensation-related, not an open-market purchase or sale, and give the right to buy shares at a fixed exercise price if vesting conditions are met.
What is the exercise price of Carmichael Gordon’s GYRE stock options?
The granted stock options carry an exercise price of $5.95 per share. This means Gordon can choose to buy Gyre Therapeutics common stock at $5.95 per share upon vesting and before expiration, regardless of the market price at that time.
How many GYRE stock options does Carmichael Gordon hold after this grant?
Following this transaction, Carmichael Gordon holds 40,000 stock options according to the filing. All of these options relate to Gyre Therapeutics common stock and result from this single grant reported on the Form 4, reflecting his current derivative position in the company.
When do Carmichael Gordon’s GYRE options vest and expire?
The 40,000 stock options vest in 12 equal monthly installments through June 10, 2027, subject to Gordon’s continued service. The options expire on June 10, 2036, giving a long window during which vested options can potentially be exercised for shares.
Is Carmichael Gordon’s GYRE Form 4 transaction a market buy or sell?
The Form 4 reports a grant of stock options as compensation, not a market buy or sell of existing shares. The transaction code is “A,” meaning grant, award, or other acquisition, and no open-market purchase or sale price is listed in the filing.